T&L Biotechnology

Recombinant Human IFN-λ1 Protein

Catalog Number: GMP-TL632

Gene Name Synonym: IL-29.

Construction: A DNA sequence encoding human IFN-λ1 (NP_742152.1) was expressed with his tag at the C terminal.

Source: Human

Expression Host: HEK293 cell

QC Testing Purity: > 95 % as determined by SDS-PAGE

Bio Activity: The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5ng/ml, corresponding to a specific activity of >2.0×105IU/mg.

Endotoxin: < 1EU per ug of the protein as determined by the LAL method.

Molecular Mass: The recombinant human IFN-λ1 contains 184 amino acids with a predicted molecular weight of 20.6 kD.

Formulation: Lyophilized from sterile PBS, pH 7.4. Normally 6 % - 8 % mannitol are added as protectants before lyophilization.

Stability & Storage: Samples are stable for up to 24 months from date of receipt at 4 ℃ and the dissolved liquid can be stored at -20℃ for 6-12 months. Avoid repeated freeze-thaw cycles.

Protein Description

IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13%a.a. sequence identity) and the type I IFN family (15-19%a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or doublestranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and upregulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.

References

1. Grzegorzewska .AE (2019) Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. Curr Med Chem 26 (25):4832-4851.
2. Hakim MS, Chen S, Ding S, Yin Y, Ikram A, Ma XX, Wang W, Peppelenbosch MP,Basal interferon signaling and therapeutic use of interferons in controlling rotavirus infection in human intestinal cellsand organoids. Pan Q.Sci Rep. 2018May 29;8(1):8341.
3. Hui X,Chen H, Huang B.Sheng Wu Gong Cheng Xue Bao. Expression purification and characterization of N-glycosylation mutant human IFN-λ1 in Pichia pastoris.2018 Apr 25;34(4):613-624.
4. Gómez-Rial J, Curras-Tuala MJ, Rivero-Calle I, Rodríguez-Tenreiro C, Redondo-Collazo L, Gómez-Carballa A, Pardo-Seco J, Salas A ,Martinón-Torres F. Rotavirus intestinal infection induces an oral mucosa cytokine response. PLoS One. 2018 Apr 5;13(4):e0195314.

Trial dosage: A customer can apply for up to five samples a year (the actual trial dosage is determined by telephone or email communication).
Scope of use: Samples are limited to testing and research purposes.
Cost: Free for samples, customer is responsible for shipping and handling charges, reference cost is $50 in the US, €60 in the EU, and $50 in other countries.
How to apply: You can apply by telephone or by email (the email application should specify the sample name, item number, contact person, telephone number, consignee address, etc.).